01 May 2006
Bifenthrin causes neurite retraction in the absence of cell death: A modelfor pesticide associated neurodegeneration.
Avishek Nandi, Daljit Chandi, Rethabile Lechesa, Stephen C. Pryor, Ashlea McLaughlin, Josephine A. Bonventre, Katherine Flynn, Benjamin S. WeeksMed Sci Monit 2006; 12(5): BR169-173 :: ID: 450282
Abstract
Background: Bifenthrin is a synthetic pyrethroid insecticide derivativeof naturally occurring pyrethrins from chrysanthemum flowers. Bifenthrin is considered relatively safeand therefore incorporated as the active ingredient in preparations sold over the counter for householduse. Recent studies have raised concern that chronic exposure to pesticides in the home setting may increasethe risk for neurodegenerative diseases. To address this concer, in the present study, bifenthrin isadded to pre-differentiated PC12 and effect of bifenthrin on the retraction of existing neurites is observeda model for neurodegeneration. Material/Methods: PC12 cells were differentiated with nerve growth factorfor twenty-four hours and then treated with what was determined to be a sublethal dose of bifenthrinfor up to an additional 48 hours. The percent of cells with neurites was assessed at various times beforeand after nerve growth factor treatment. Bifenthrin toxicity was determined using trypan blue exclusion.Results: Bifenthrin was not toxic to PC12 cells at concentrations ranging from 1x10[sup]-10[/sup] M to 1x10[sup]-4[/sup]M. Twenty-four hours after nerve growth factor treatment, a maximum percent of cells had formed neuritesand with a treatment of 1x10[sup]-5[/sup] M bifenthrin, approximately 80% of these neurites retracted in within12 additional hours and almost all neurites had retracted within 48 hours. Trypan exclusion showed thatthese cells were viable. Conclusions: These data show that bifenthrin can stimulate the retraction ofneurites in the absence of frank toxicity.
Keywords: Cell Survival - drug effects, Insecticides - toxicity, Lindane - toxicity, Models, Neurological, Nerve Degeneration - pathology, Nerve Growth Factor - pharmacology, Neurites - pathology, Neurons - pathology, Pyrethrins - toxicity
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
08 Feb 2024 : Database Analysis
Comparative Accuracy of Intraoral and Extraoral Digital Workflows for Short Span Implant Supported Fixed Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943706
08 Feb 2024 : Clinical Research
Serum Selenium Concentration as a Potential Diagnostic Marker for Early-Stage Colorectal Cancer: A Comparat...Med Sci Monit In Press; DOI: 10.12659/MSM.942882
09 Feb 2024 : Clinical Research
Factors Influencing the Occurrence of Intraoperative Hypothermia in Patients Undergoing General Anesthesia ...Med Sci Monit In Press; DOI: 10.12659/MSM.943463
13 Feb 2024 : Clinical Research
A Retrospective Study to Compare the Glasgow Coma Score, Pediatric Trauma Score, and Injury Severity Score ...Med Sci Monit In Press; DOI: 10.12659/MSM.943501
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952